Jeff Lockwood

1 week ago | globenewswire.com | BlueRock Therapeutics |Jeff Lockwood

Cambridge, MA USA, April 16, 2025 (GLOBE NEWSWIRE) -- BlueRock Therapeutics LP, a clinical-stage cell therapy company and wholly owned subsidiary of Bayer AG, today announced the publication of the 18-month data from its Phase 1 exPDite clinical trial for bemdaneprocel in the journal Nature.

Sep 3, 2024 | globenewswire.com | BlueRock Therapeutics |Jeff Lockwood

Cambridge, MA USA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned, independently operated subsidiary of Bayer AG, today announced the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for OpCT-001, an investigational induced pluripotent stem cell (iPSC)-derived cell therapy for the treatment of primary photoreceptor diseases.

May 30, 2024 | globenewswire.com | BlueRock Therapeutics |Jeff Lockwood

Berlin, Germany and Cambridge, MA, USA, May 30, 2024 (GLOBE NEWSWIRE) -- Bayer AG and BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned independently operated subsidiary of Bayer AG, announced today that BlueRock’s investigational cell therapy bemdaneprocel for the treatment of Parkinson’s disease has been granted Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA).

Mar 27, 2023 | aol.com | Jeff Lockwood

Mar 27, 2023 | yahoo.com | Jeff Lockwood